Polyurethane Biomaterials with Heparin Binding Sites

Information

  • Research Project
  • 6550259
  • ApplicationId
    6550259
  • Core Project Number
    R43GM066630
  • Full Project Number
    1R43GM066630-01
  • Serial Number
    66630
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/2002 - 22 years ago
  • Project End Date
    1/31/2003 - 21 years ago
  • Program Officer Name
    LINK, REBECCA P.
  • Budget Start Date
    8/1/2002 - 22 years ago
  • Budget End Date
    1/31/2003 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/29/2002 - 22 years ago

Polyurethane Biomaterials with Heparin Binding Sites

DESCRIPTION (provided by applicant):It is well known that the thrombo-resistance of polymeric biomaterials can be improved by surface endpoint immobilization of heparin. Current heparinization methods are complex and costly, and may degrade the mechanical properties of the base polymer. The proposed study will determine the feasibility of synthesizing tough, thermoplastic polyurethane biomaterials with 'built-in' binding sites for heparin. Heparinization will be achieved by simply soaking the device/component made from the subject polymer, in an aqueous heparin solution. A diamine-diamide-diol (PIME), which has an established ability to bind heparin, will replace some of the normal diol 'chain extender' in a well-established biomedical polycarbonate-urethane. Surfaces of the resulting PIME-containing polyurethanes will be characterized by Sum Frequency Generation Spectroscopy (SFG), Contact Angle Goniometry, and Atomic Force Microscopy. Heparin activity will be determined by Activated Partial Thromboplastic Time (APTT) on freshly synthesized and sterilized device analogues. Preliminary results indicate surface PIME can be easily distinguished from the base polyurethane by SFG. Also, non-sterile heparinized PIME-containing polyurethanes exhibit an APTT of >500 seconds compared to <55 seconds for polyurethanes without PIME. Biomaterials with inherent affinity for heparin will reduce the cost of surface heparinization and are therefore applicable to a wide range of blood-contact medical devices and prostheses.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    POLYMER TECHNOLOGY GROUP, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BERKELEY
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94710
  • Organization District
    UNITED STATES